Research Paper Volume 14, Issue 13 pp 5406—5416

circEPSTI1 promotes tumor progression and cisplatin resistance via upregulating MSH2 in cervical cancer

class="figure-viewer-img"

Figure 2. Inhibition of circEPSTI1 attenuates the progress and cisplatin resistance of cervical cancer cells. (A) The effect of shRNA knockdown of circEPSTI1 was assessed in SiHa, as well as HT-3 cell lines of cervical cancer, assessing via qRT-PCR. (B) CCK-8 assay was adopted to test the cell growth rate in SiHa along with HT-3 cell lines of cervical cancer. (C, D) Colony-formation experiments were conducted in SiHa, as well as HT-3 cell lines of cervical cancer. (E, F) Transwell assay for assessment of the metastasis potential of SiHa cervical cancer cell line. (G, H) Inhibition of circEPSTI1 remarkably increased the responsivity of cervical cancer to cisplatin treatment in SiHa along with HT-3 cervical cancer cell lines.